JP4652808B2 - ナイセリアＮｓｐＡタンパク質をリフォールディングする方法 - Google Patents

ナイセリアＮｓｐＡタンパク質をリフォールディングする方法 Download PDF

Info

Publication number
JP4652808B2
JP4652808B2 JP2004532178A JP2004532178A JP4652808B2 JP 4652808 B2 JP4652808 B2 JP 4652808B2 JP 2004532178 A JP2004532178 A JP 2004532178A JP 2004532178 A JP2004532178 A JP 2004532178A JP 4652808 B2 JP4652808 B2 JP 4652808B2
Authority
JP
Japan
Prior art keywords
protein
nspa
neisseria
present
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004532178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006511463A5 (enExample
JP2006511463A (ja
Inventor
ビーマンズ，ラルフ
ボス，マルティーヌ
デノエル，フィリップ
フェロン，クリスティアーヌ
ゴラジ，カリーヌ
プールマン，ジャン
トマセン，ジャン
ウェイナンツ，ヴィンセント
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
ユトレヒト ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, ユトレヒト ユニバーシティー filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2006511463A publication Critical patent/JP2006511463A/ja
Publication of JP2006511463A5 publication Critical patent/JP2006511463A5/ja
Application granted granted Critical
Publication of JP4652808B2 publication Critical patent/JP4652808B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2004532178A 2002-08-30 2003-08-28 ナイセリアＮｓｐＡタンパク質をリフォールディングする方法 Expired - Fee Related JP4652808B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0220197.8A GB0220197D0 (en) 2002-08-30 2002-08-30 Refolding method
PCT/EP2003/010085 WO2004020452A2 (en) 2002-08-30 2003-08-28 Method for refolding neisserial nspa protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010226544A Division JP2011057679A (ja) 2002-08-30 2010-10-06 ナイセリアＮｓｐＡタンパク質をリフォールディングする方法

Publications (3)

Publication Number Publication Date
JP2006511463A JP2006511463A (ja) 2006-04-06
JP2006511463A5 JP2006511463A5 (enExample) 2006-09-21
JP4652808B2 true JP4652808B2 (ja) 2011-03-16

Family

ID=9943240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004532178A Expired - Fee Related JP4652808B2 (ja) 2002-08-30 2003-08-28 ナイセリアＮｓｐＡタンパク質をリフォールディングする方法
JP2010226544A Pending JP2011057679A (ja) 2002-08-30 2010-10-06 ナイセリアＮｓｐＡタンパク質をリフォールディングする方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010226544A Pending JP2011057679A (ja) 2002-08-30 2010-10-06 ナイセリアＮｓｐＡタンパク質をリフォールディングする方法

Country Status (8)

Country Link
US (2) US20080025993A1 (enExample)
EP (1) EP1532168B1 (enExample)
JP (2) JP4652808B2 (enExample)
AU (1) AU2003273854A1 (enExample)
CA (1) CA2496045A1 (enExample)
ES (1) ES2505692T3 (enExample)
GB (1) GB0220197D0 (enExample)
WO (1) WO2004020452A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011057679A (ja) * 2002-08-30 2011-03-24 Glaxosmithkline Biologicals Sa ナイセリアＮｓｐＡタンパク質をリフォールディングする方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
AU2010315115B2 (en) 2009-11-06 2015-01-29 Children's Hospital & Research Center At Oakland T-cell stimulating protein B and methods of use
US20130273607A1 (en) * 2010-10-20 2013-10-17 Medimmune, Llc Methods for processing inclusion bodies
CN104428008B (zh) 2012-05-24 2020-10-09 美国政府(由卫生和人类服务部的部长所代表) 多价脑膜炎球菌缀合物及制备缀合物的方法
EP3061296B1 (en) * 2014-02-10 2018-06-06 MediaTek Inc. Method for identifying source bss in wlan
BR102018003245A2 (pt) * 2018-02-20 2019-09-10 Fundação Oswaldo Cruz oligonucleotídeo, conjunto de oligonucleotídeos, método para detecção simultânea de neisseria meningitidis, streptococcus pneumoniae e haemophilus influenzae, e, kit.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117483A (en) * 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
DK2270173T3 (en) * 1999-05-19 2016-03-07 Glaxosmithkline Biolog Sa Neisserial combination compositions
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0007432D0 (en) * 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0220197D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Refolding method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011057679A (ja) * 2002-08-30 2011-03-24 Glaxosmithkline Biologicals Sa ナイセリアＮｓｐＡタンパク質をリフォールディングする方法

Also Published As

Publication number Publication date
US20080025993A1 (en) 2008-01-31
WO2004020452A3 (en) 2004-08-19
GB0220197D0 (en) 2002-10-09
US20100291137A1 (en) 2010-11-18
EP1532168A2 (en) 2005-05-25
JP2006511463A (ja) 2006-04-06
EP1532168B1 (en) 2014-07-23
ES2505692T3 (es) 2014-10-10
AU2003273854A8 (en) 2004-03-19
AU2003273854A1 (en) 2004-03-19
CA2496045A1 (en) 2004-03-11
JP2011057679A (ja) 2011-03-24
WO2004020452A2 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
JP5789203B2 (ja) ワクチン組成物
JP5173194B2 (ja) ワクチン
JP2017114874A (ja) 免疫原性組成物
JP2011057679A (ja) ナイセリアＮｓｐＡタンパク質をリフォールディングする方法
EP1572729B1 (en) Mutant frpb protein and refolding method
ZA200500927B (en) Neisserial vaccine compositions comprising a combination of antigens
HK1077014B (en) Neisserial vaccine compositions comprising a combination of antigens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090817

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100630

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101006

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101116

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101216

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131224

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees